MedTrace Logo

Impact of Human Papillomavirus Carriage on IVF/ICSI Results (HPV AMP)

NCT06550531 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 618

Last updated 2024-08-13

No results posted yet for this study

Summary

The prevalence of the papilloma virus in the general population is 12%. This virus is known to impair male fertility but its impact on female infertility remains uncertain. This is a public health problem since there is a vaccination protocol. Demonstrating the impact of the human papillomavirus on fertility would be an argument in favor of vaccination.

Conditions

Sponsors & Collaborators

  • University Hospital, Brest

    lead OTHER

Eligibility

Min Age
25 Years
Max Age
38 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-04
Primary Completion
2026-02-04
Completion
2026-02-04

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06550531 on ClinicalTrials.gov